Prolonged (PI) vs short-term irinotecan (STI) administration: The Martha trial—A SICOG (Southern Italy Cooperative Oncology Group) randomized phase III study in the first-line setting of metastatic colorectal cancer (mCRC) patients (pts).

Vincenzo Formica,Maria Teresa Ionta,Vessia Giacomo,L. Maiorino,R. Casaretti,Donato Natale,Giuseppe Barberis,Gianfranco Filippelli,Ettore Greco,Livio Blasi,S. Mancarella,Anna Russo,Enrico Barbato,Liberato Di Lullo,Mario Roselli

Prolonged (PI) vs short-term irinotecan (STI) administration: The Martha trial—A SICOG (Southern Italy Cooperative Oncology Group) randomized phase III study in the first-line setting of metastatic colorectal cancer (mCRC) patients (pts).

2017

Vincenzo Formica
Maria Teresa Ionta
Vessia Giacomo
L. Maiorino
R. Casaretti
Donato Natale
Giuseppe Barberis
Gianfranco Filippelli
Ettore Greco
Livio Blasi
S. Mancarella
Anna Russo
Enrico Barbato
Liberato Di Lullo
Mario Roselli

3552Background: FOLFIRI+bevacizuamab(B) is a standard first-line regimen for mCRC pts. It should be delivered until progression, though an early switch to a de-intensified maintenance regimen is of...

Keywords:

Pi
Colorectal cancer
Cancer research
Physical therapy
Irinotecan
Medicine
Regimen
Oncology
first line
FOLFIRI
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations